Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler, +23

The Lancet Oncology

Lux-lung 3Lux-lung 6MedicinePathologyBronchial Neoplasm +7

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Keunchil Park, Eng-Huat Tan, Kenneth J. O’Byrne, +20

The Lancet Oncology

OncologyPhase 2BPathologyBronchial NeoplasmAfatinib Versus Gefitinib +6

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

James Chih‐Hsin Yang, Lecia V. Sequist, Sarayut Lucien Geater, +10

The Lancet Oncology

Lux-lung 6MedicinePathologyClinical ActivityCancer Genomics +9

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

Karen Kelly, Nasser K. Altorki, Wilfried Eberhardt, +12

Journal of Clinical Oncology

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

James Chih‐Hsin Yang, Jin‐Yuan Shih, Wu‐Chou Su, +13

The Lancet Oncology

Advanced Lung DiseaseMedicineLung AdenocarcinomaPathologyLux-lung 2 +8

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations

Chao‐Hua Chiu, Cheng‐Ta Yang, Jin‐Yuan Shih, +17

Journal of Thoracic Oncology

MedicineReceptor Tyrosine KinaseCancer GrowthPathologyAdvanced Lung Adenocarcinomas +7

First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer

Keunchil Park, Chong‐Jen Yu, Sang-We Kim, +10

JAMA Oncology

Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial–mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma

Guang‐Yuh Chiou, Jong‐Yuh Cherng, Han‐Shui Hsu, +12

Journal of Controlled Release

Tumor BiologyCancer Stem-like PropertiesPolymer-drug ConjugateLung AdenocarcinomaCancer Cell Biology +8

Multiple primary malignancies involving lung cancer—clinical characteristics and prognosis

Yung-Yang Liu, Yuh-Min Chen, Sang-Hue Yen, +2

Lung Cancer

MedicinePathologyPulmonary BlastomaOncologyLung Cancer +2

A Randomized Trial of Different Docetaxel Schedules in Non-small Cell Lung Cancer Patients Who Failed Previous Platinum-Based Chemotherapy

Yuh-Min Chen, Jen-Fu Shih, Reury-Perng Perng, +2

CHEST Journal

OncologyCancer ManagementPrevious Platinum-based ChemotherapyClinical TrialsDifferent Docetaxel Schedules +8